← Back to Search

Behavioral Intervention

Financial incentive (loss) for Type 1 Diabetes (InvesT1D Trial)

N/A
Waitlist Available
Research Sponsored by Harvard Pilgrim Health Care
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Speaks English fluently
Cognitively able to participate in incentive program and complete surveys.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

InvesT1D Trial Summary

This study is evaluating whether financial incentives can help motivate adolescents with type 1 diabetes to improve their self-care.

Eligible Conditions
  • Type 1 Diabetes

InvesT1D Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

InvesT1D Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HbA1c
Secondary outcome measures
DFCS
Glucose monitoring
Insulin Administration
+3 more

InvesT1D Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Loss-framed incentiveExperimental Treatment1 Intervention
Participants will start off at the maximum incentive balance at the beginning of the treatment period and for each day that participants' fail to meet goals, value will be subtracted from their incentive balance over the 12-week. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits.
Group II: Gain-framed incentiveExperimental Treatment1 Intervention
Participants will start off with nothing at the beginning of the treatment period. For each day that participants' meet goals, value will be added to their incentive balance. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits.
Group III: ControlActive Control1 Intervention
Usual care reflects the standard treatment currently provided to T1D patients. All adolescent participants in the study will have access to the multidisciplinary care team including a diabetes provider, registered diabetes nurse, social worker, and nutritionist. Telephone consultations are available 24/7 as often as necessary between clinic visits.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Financial incentive (gain)
2020
N/A
~40
Financial incentive (loss)
2020
N/A
~40

Find a Location

Who is running the clinical trial?

Seattle Children's HospitalOTHER
299 Previous Clinical Trials
5,216,897 Total Patients Enrolled
Harvard Pilgrim Health CareLead Sponsor
54 Previous Clinical Trials
27,781,497 Total Patients Enrolled
Seattle Children's Research Institute (SCRI)OTHER
8 Previous Clinical Trials
697 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~9 spots leftby Mar 2025